Key Takeaways:
A class action lawsuit was filed against Immutep Limited, alleging the company misled investors about its TACTI-004 trial, leading to significant losses after the trial was halted.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, one of the firms that has filed a lawsuit.
The lawsuit, filed on behalf of investors who purchased Immutep securities between March 24, 2025, and March 12, 2026, claims the company concealed the poor prospects of its TACTI-004 trial. On March 13, 2026, Immutep announced the trial's discontinuation, causing its American Depositary Receipt (ADR) price to fall 82.6% to $0.48.
Investors who suffered losses have until July 6, 2026, to file a motion to be appointed as lead plaintiff. The lawsuits seek to recover damages for investors who lost money due to the alleged misrepresentations.
Multiple law firms, including Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, and Holzer & Holzer, LLC, have announced investigations and filed lawsuits. The core of the allegations is that Immutep, despite knowing the increasing risk of failure, continued to make positive statements about the TACTI-004 trial's progress.
The complaint highlights that Immutep's statements about "strong operational progress" and the timing of the interim futility analysis were baseless given the internal clinical data. The lawsuits claim that the company's positive outlook was based on prior, unrelated studies, which misled investors about the TACTI-004 trial's viability.
The sharp decline in Immutep's stock price on March 13, 2026, directly followed the company's press release about the Independent Data Monitoring Committee's recommendation to discontinue the trial for futility. This event erased significant shareholder value and triggered the legal actions.
This legal battle adds to the challenges for the biotechnology company, which now faces a lengthy and potentially costly litigation process. The outcome of the class action lawsuit could have significant financial implications for Immutep and will be closely watched by investors. The next key date for the case is the July 6, 2026, deadline for lead plaintiff applications.
This article is for informational purposes only and does not constitute investment advice.
